- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00129558
A Study to Evaluate PT-523 in Patients With Refractory Leukemia
December 2, 2013 updated by: Spectrum Pharmaceuticals, Inc
A Phase I/II Study of PT-523 in Patients With Refractory Leukemia
This Phase I/II, multi-centered, non-randomized, trial is designed to determine a safe dose of PT-523 for subjects, and to make preliminary evaluations on the activity of PT-523 as therapy in subjects with refractory leukemia.
Study Overview
Study Type
Interventional
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033-1048
- USC, Kennth Norris Jr. Comprehensive Cancer Center
-
Los Angeles, California, United States, 90095-3075
- UCLA School of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, United States, 27157-1082
- Wake Forest University School of Medicine Comprehensive Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas M. D. Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Relapsed/refractory leukemias including acute non-lymphocytic leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia in blastic phase (CML-BP) for which no standard therapies are anticipated to result in a durable remission; or poor-risk myelodysplasia (MDS) patients to include refractory anemia with excess blasts (RAEB) or excess blasts in transformation (RAEBT) and chronic myelomonocytic leukemia (CMML) who are either relapsed/refractory or who refuse/are not eligible for frontline therapy.
- Only patients with refractory ALL or CML in lymphoid blastic phase are eligible for phase II.
- ECOG performance status 0 - 2.
- Adequate organ function and bone marrow reserve.
- At least 4 weeks must have elapsed from the time of major surgery.
- Use of appropriate contraceptive method.
- Signed patient informed consent.
Exclusion Criteria:
- Known human immunodeficiency virus (HIV).
- Active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure.
- Patients receiving any other standard or investigational treatment for their leukemia other than corticosteriods, hydroxyurea, and 6-mercaptopurine.
- Any medical condition which, in the opinion of the investigator, places the patient at an unacceptably high risk for toxicities.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2005
Primary Completion (Actual)
September 1, 2011
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
August 10, 2005
First Submitted That Met QC Criteria
August 11, 2005
First Posted (Estimate)
August 12, 2005
Study Record Updates
Last Update Posted (Estimate)
December 4, 2013
Last Update Submitted That Met QC Criteria
December 2, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HBS103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationActive, not recruitingAcute Myelogenous LeukemiaUnited States
-
Massachusetts General HospitalCompleted
-
Beijing Boren HospitalRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse LeukemiaChina
-
Kinex Pharmaceuticals Inc.CompletedAcute Myelogenous LeukemiaUnited States
Clinical Trials on PT-523 for Injection
-
Spectrum Pharmaceuticals, IncWithdrawnNon-Small-Cell Lung CarcinomaUnited States, Russian Federation
-
Spectrum Pharmaceuticals, IncNational Cancer Institute (NCI)Terminated
-
Promontory Therapeutics Inc.Active, not recruitingUrogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Advanced Solid Tumors | mCRPC | Metastatic Castrate-resistant Prostate Cancer | CRPC | PT-112United States, France
-
SciClone PharmaceuticalsUnknown
-
Instituto Brasileiro de Controle do CancerRecruitingSurgery | SARS-CoV-2 | OncologyBrazil
-
Shin Kong Wu Ho-Su Memorial HospitalCompletedRotator Cuff Tear | Ultrasonography | Rotator Cuff TendinopathyTaiwan
-
Kinex Medical Company, LLCHealth Factors IncActive, not recruitingOsteoarthritis, KneeUnited States
-
Shanghai Gebaide Biotechnology Co., Ltd.UnknownNon-small-cell Lung Cancer (NSCLC) Stage IVChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
AstraZenecaCompletedHealthy Elderly | Mild-Moderate Alzheimer's DiseaseUnited States